In the case of disease recurrence of platinum-sensitive high-grade epithelial ovarian cancer, the PARPi olaparib, niraparib, and rucaparib are approved as maintenance therapy after response to second-line platinum-based chemotherapy, independently of the BRCA1/2 mutational status [8,9,10,11]. The gene discussed is BRCA1; the disease is ovarian carcinoma.